Promise Proteomics positions itself on the diagnostics and personalised medicines market with its “mAb-X-mise” range of products
Grenoble (France), 26th november
Promise Proteomics, the Grenoble-based experts in protein quantification in biological samples, announce that they are launching their first product on the diagnostics and personalised medicines market with their mAb-X-mise range of diagnostic kits for the therapeutic follow-up of biologics.
mAb-X-mise: the right dose of the right drug for the right patient
The ambition of the mAb-X-mise range developed by Promise Proteomics is to tailor each patient’s dose to allow further advances in the personalised management of diseases eligible for treatment with biological therapies. Since the start of the millennium, personalised medicine has made it possible to provide “the right drug for the right patient”. mAb-X-mise diagnostic kits take us one step further: medicine can now be personalised with “the right dose of the right drug for the right patient”.
The Chief Scientific Officer at Promise Proteomics, Dorothée Lebert, very rapidly understood the potential of being able to monitor the pharmacodynamics of biologics using a robust and easy-to-use technique. This type of approach will allow clinicians to regularly monitor levels of the therapeutic antibodies they prescribe, allowing them to adapt their clinical management to each individual patient.
mAb-X-mise: the first range of diagnostic kits from Promise Proteomics
The range developed by Promise Proteomics comprises two products: a kit specifically designed to monitor therapeutic antibodies prescribed to treat inflammatory diseases, and a second kit targeting antibodies prescribed in oncology.
“We were lucky enough to be able to collaborate very early on with health care professionals interested in our technology. With their input, we matured our project, and our first two products in this range are the fruit of these collaborations explains Dorothée Lebert, CSO of Promise Proteomics.
The kit for inflammatory diseases allows quantification of two therapeutic antibodies, whereas the oncology kit can be used to monitor the six therapeutic antibodies most commonly used today.
Promise Proteomics has also capitalised on its technological advances by developing new applications and ranges of products.
mAb-X-mise: a state-of-the-art technological innovation at the service of personalised medicine
The mAb-X-mise kit is based on state-of-the-art technology - mass spectrometry - and on standard proteins developed by Promise Proteomics. One of the advantages of the approach designed is that it can be used to simultaneously quantify several therapeutic antibodies prescribed by the physician. This all-in-one approach, termed multiplexing, is particularly advantageous for patients treated with combination therapies, who simultaneously receive doses of several therapeutic antibodies. Combination therapies are increasingly used in oncology, and today mAb-X-mise is the only kit to allow their therapeutic monitoring.
“The technological innovation behind mAb-X-mise revolutionises monitoring of therapeutic antibodies by making a state-of-the-art technology accessible in everyday clinical practice” indicates Eric Rougemond, CEO of Promise Proteomics and the Aguettant group.
mAb-X-mise: a new leader in the emerging market of therapeutic follow-up of biologics
The mAb-X-mise technology has already been successfully deployed in several European hospitals. Clinical laboratories performing therapeutic monitoring of drug levels are equipped with mass spectrometers and already have the expertise to quantify small molecules, garnered over several years. User-feedback on the mAb-X-mise kit is very positive and reflects its robustness and its analytical performance.
The technology is also compatible with the constraints of clinical practice, with a 30-h turnaround time between blood sampling and assay results. mAb-X-mise thus combines state of the art technology with practicality.
In 2022, the biologics sector alone will represent 40% of the worldwide drugs market. On the strength of its expertise and in a favourable context, Promise Proteomics aims to become the leader in therapeutic follow-up of biologics.
About
Promise Proteomics was created in 2010 as a spin-off of CEA Grenoble. This medtech is currently wholly owned by the Aguettant group and is directed by Dr Eric Rougemond. Its business model is based on a range of services in bioproduction and on the development of products to label and quantify proteins in biological samples. Since 2013, Promise has been a partner in an innovative and ambitious R&D programme which has allowed it to develop its technology, on which the diagnostic kits for personalised medical applications are based. Capitalising on its unique know- how in the production of internal standards for protein assays and its recognised expertise in mass spectrometry-based quantification methods, Promise Proteomics is placing its skills at the service of health care professionals through its mAb-X-mise kits.
Press contact
Ophélie Philipot ophelie.philipot@comopi.tech